Abstract
New approaches to atherosclerosis-related diseases include novel uses of proven treatments and development of innovative agents. Several commonly used cardiovascular drugs such as dihydropyridine calcium antagonists, ACE inhibitors containing the sulphydryl group, or highly lipophilic beta-blockers have some antiatherosclerotic activities. Moreover, new clinical trials suggesting that additional reduction of lowdensity lipoprotein cholesterol levels with statin therapy results in additional benefit in coronary heart disease prevention. Notably, new cholesterol transport or bile acid transport inhibitors have been found to produce significant reductions in intestinal cholesterol absorption and experimental atherosclerosis. Inhibitors of acyl coenzyme A:cholesterol acyltransferase, which can reduce cholesterol storage in macrophages and in arterial lesions, have also been developed. Finally, newer therapeutical strategies against atherogenesis may include the use of antioxidants and cholestyramine during pregnancy or the development of metalloproteinase inhibitors.
Keywords: atherosclerosis, statins, ace-inhibitors, antioxidants
Current Medicinal Chemistry
Title: New Trends in Anti-Atherosclerotic Agents
Volume: 12 Issue: 15
Author(s): C. Napoli, V. Sica, O. Pignalosa and F. de Nigris
Affiliation:
Keywords: atherosclerosis, statins, ace-inhibitors, antioxidants
Abstract: New approaches to atherosclerosis-related diseases include novel uses of proven treatments and development of innovative agents. Several commonly used cardiovascular drugs such as dihydropyridine calcium antagonists, ACE inhibitors containing the sulphydryl group, or highly lipophilic beta-blockers have some antiatherosclerotic activities. Moreover, new clinical trials suggesting that additional reduction of lowdensity lipoprotein cholesterol levels with statin therapy results in additional benefit in coronary heart disease prevention. Notably, new cholesterol transport or bile acid transport inhibitors have been found to produce significant reductions in intestinal cholesterol absorption and experimental atherosclerosis. Inhibitors of acyl coenzyme A:cholesterol acyltransferase, which can reduce cholesterol storage in macrophages and in arterial lesions, have also been developed. Finally, newer therapeutical strategies against atherogenesis may include the use of antioxidants and cholestyramine during pregnancy or the development of metalloproteinase inhibitors.
Export Options
About this article
Cite this article as:
Napoli C., Sica V., Pignalosa O. and Nigris de F., New Trends in Anti-Atherosclerotic Agents, Current Medicinal Chemistry 2005; 12 (15) . https://dx.doi.org/10.2174/0929867054367257
DOI https://dx.doi.org/10.2174/0929867054367257 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Current Vascular Pharmacology Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque
Current Drug Targets Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Dietary Factors Influencing Magnesium Absorption in Humans
Current Nutrition & Food Science Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Current Vascular Pharmacology